Skip to main content

Therapeutic strategies using vegf substitutes and gene therapies to maintain the integrity of the arterial wall

Objective

The Partners have proposed a new hypothesis whereby vascular endothelial growth factor (VEGF) is arterioprotective in intimae hyperplasic and arteriosclerosis. That cell signalling of the VEGF family, which underlines the production of NO and PGI_2, is the basis of the arterioprotective effect will be elucidated. Peptides will be synthesised and used as probes and as substitutes for the VEGF receptors in functional studies. The peptides will be the basis of future cytoprotective medicines. Rabbit and mice models of VEGF protective functions will be used. Novel VEGF- and PIGF-induced genes will be discovered leading to novel therapies. Transgenic mouse models lacking or expressing mutant forms of the VEGF family of genes will be used to evaluate the vasculoprotective role in intimae hyperplasic and arteriosclerosis. This project will elucidate the mechanisms involved in arterioprotection by VEGF and produce novel arterioprotective therapeutics.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

Birkbeck College, University of London
Address
Malet Street, Bloomsbury
WC1E 7HX London
United Kingdom

Participants (3)

FLANDERS INTERUNIVERSITY INSTITUTE FOR BIOTECHNOLOGY VZW
Belgium
Address
Rijvisschestraat 120
9052 Zwijnaarde
UNIVERSITY OF KUOPIO
Finland
Address
Savilahdentie 9
1627 Kuopio
University of Ulm
Germany
Address
Albert-einstein-allee 11
89070 Ulm